Enclomiphene and LGD-4033 Interaction
Enclomiphene and LGD-4033 have a compatible interaction with 90% confidence. Enclomiphene is commonly used as post-cycle therapy (PCT) following LGD-4033 cycles to restore endogenous testosterone production. A typical PCT protocol is 12.5-25 mg/day enclomiphene for 4-6 weeks, starting approximately 2-3 days after the last LGD-4033 dose (the shorter half-life of LGD-4033 compared to RAD-140 means PCT can begin sooner). Some users also run low-dose enclomiphene on-cycle to mitigate suppression, though this approach is less studied. Both compounds affect the gonads, so monitoring these systems is recommended.
Compound Profiles
Enclomiphene
Selective Estrogen Receptor Modulator | Testosterone & Fertility Support
Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
View full profileLGD-4033
Selective Androgen Receptor Modulator | Lean Mass
LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Enclomiphene with LGD-4033?
Yes, Enclomiphene and LGD-4033 can generally be taken together. Enclomiphene is commonly used as post-cycle therapy (PCT) following LGD-4033 cycles to restore endogenous testosterone production. A typical PCT protocol is 12.5-25 mg/day enclomiphene for 4-6 weeks, starting approximately 2-3 days after the last LGD-4033 dose (the shorter half-life of LGD-4033 compared to RAD-140 means PCT can begin sooner). Some users also run low-dose enclomiphene on-cycle to mitigate suppression, though this approach is less studied.
Is Enclomiphene and LGD-4033 safe together?
Based on documented research, this combination is considered compatible. However, shared safety flags include: hepatotoxic, teratogenic. Monitor accordingly.
What are the interactions between Enclomiphene and LGD-4033?
Enclomiphene is commonly used as post-cycle therapy (PCT) following LGD-4033 cycles to restore endogenous testosterone production. A typical PCT protocol is 12.5-25 mg/day enclomiphene for 4-6 weeks, starting approximately 2-3 days after the last LGD-4033 dose (the shorter half-life of LGD-4033 compared to RAD-140 means PCT can begin sooner). Some users also run low-dose enclomiphene on-cycle to mitigate suppression, though this approach is less studied. This assessment has 90% confidence and is based on documented research data.
How should I time Enclomiphene and LGD-4033?
Enclomiphene has a half-life of ~10 hours and LGD-4033 has a half-life of ~24-36 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.